- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
To Ablate, or Not to Ablate? How Will You Answer the Question?
Ablation therapy may be an option for these two patients with heart disease. What is your recommendation? And, does the evidence support it?
Mr Jones and Mrs Smith have different types of heart disease but both also have atrial fibrillation (AF) as well that creates significant additional burden. In each case a decision must be made about an ablation procedure. At the 2015 American College of Cardiology annual meeting in March, research was presented that provides evidence for the correct answer in each of the following scenarios. Choose your option, then find out what the research revealed.
Mr Jones is 68 years old and has ischemic cardiomyopathy, with LVEF of 30%, CRT-D, and NYHA class III heart failure (HF).
Which of the following may be a preferred treatment option for reducing AF arrhythmia burden in such a patient?
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial
September 2nd 2025At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
